Revisiting fetal hemoglobin inducers in beta-hemoglobinopathies: a review of natural products, conventional and combinatorial therapies

Beta-hemoglobinopathies exhibit a heterogeneous clinical picture with varying degrees of clinical severity. Pertaining to the limited treatment options available, where blood transfusion still remains the commonest mode of treatment, pharmacological induction of fetal hemoglobin (HbF) has been a luc...

Full description

Saved in:
Bibliographic Details
Published in:Molecular biology reports 2022-03, Vol.49 (3), p.2359-2373
Main Authors: Mukherjee, Mandrita, Rahaman, Motiur, Ray, Suman Kumar, Shukla, Praphulla Chandra, Dolai, Tuphan Kanti, Chakravorty, Nishant
Format: Article
Language:English
Subjects:
Animal Anatomy
Animal Biochemistry
Bioactive compounds
Biological Products - pharmacology
Biological Products - therapeutic use
Biomedical and Life Sciences
Biosensors
Blood transfusion
Cytotoxicity
Drug screening
Fetal Hemoglobin
Fetuses
Hemoglobin
Hemoglobinopathies - drug therapy
Histology
Humans
Life Sciences
Morphology
Natural products
Resveratrol
Review
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Beta-hemoglobinopathies exhibit a heterogeneous clinical picture with varying degrees of clinical severity. Pertaining to the limited treatment options available, where blood transfusion still remains the commonest mode of treatment, pharmacological induction of fetal hemoglobin (HbF) has been a lucrative therapeutic intervention. Till now more than 70 different HbF inducers have been identified. The practical usage of many pharmacological drugs has been limited due to safety concerns. Natural compounds, like Resveratrol, Ripamycin and Bergaptene, with limited cytotoxicity and high efficacy have started capturing the attention of researchers. In this review, we have summarized pharmacological drugs and bioactive compounds isolated from natural sources that have been shown to increase HbF significantly. It primarily discusses recently identified synthetic and natural compounds, their mechanism of action, and their suitable screening platforms, including high throughput drug screening technology and biosensors. It also delves into the topic of combinatorial therapy and drug repurposing for HbF induction. Overall, we aim to provide insights into where we stand in HbF induction strategies for treating β-hemoglobinopathies.
ISSN:0301-4851
1573-4978
DOI:10.1007/s11033-021-06977-8